Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXT-CAR NK cells
- Development stage
- Unknown
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CXT-CAR NK cells are a form of chimeric antigen receptor-natural killer (CAR-NK) cell therapy, an advanced immunotherapy designed to target cancer cells. These therapies genetically engineer natural killer (NK) cells to express chimeric antigen receptors (CARs), which enable the immune cells to recognize and kill tumor-specific antigens in a human leukocyte antigen (HLA)-unrestricted manner. CAR-NK cell therapy combines the innate cytotoxicity of NK cells with targeted precision against cancer, offering advantages such as reduced risk of graft-versus-host disease and lower incidence of cytokine release syndrome compared to CAR-T therapies. The approach is being developed primarily for hematologic malignancies and solid tumors, with ongoing research focusing on improving activation, proliferation, persistence, and overcoming tumor microenvironment challenges. Cytokine support strategies like IL-2 variants are explored to enhance efficacy while minimizing regulatory T cell activation.
- Other names
- CXT-CAR NK cells
Beyond the preview
Go deeper on CXT-CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXT-CAR NK cells.